Literature DB >> 2205201

Preparation and characterization of human interleukin-5 expressed in recombinant Escherichia coli.

A E Proudfoot1, D Fattah, E H Kawashima, A Bernard, P T Wingfield.   

Abstract

The gene coding for human interleukin-5 was synthesized and expressed in Escherichia coli under control of a heat-inducible promoter. High-level expression, 10-15% of total cellular protein, was achieved in E. coli. The protein was produced in an insoluble state. A simple extraction, renaturation and purification scheme is described. The recombinant protein was found to be a homodimer, similar to the natural murine-derived protein. Despite the lack of glycosylation, high specific activities were obtained in three 'in vitro' biological assays. Physical characterization of the protein showed it to be mostly alpha-helical, supporting the hypothesis that a conformational similarity exists among certain cytokines.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2205201      PMCID： PMC1131729          DOI： 10.1042/bj2700357

Source DB:  PubMed          Journal:  Biochem J        ISSN： 0264-6021            Impact factor:   3.857


  26 in total

1.  Eosinophil differentiation factor also has B-cell growth factor activity: proposed name interleukin 4.

Authors:  C J Sanderson; A O'Garra; D J Warren; G G Klaus
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

2.  Optimizing the expression in E. coli of a synthetic gene encoding somatomedin-C (IGF-I).

Authors:  G Buell; M F Schulz; G Selzer; A Chollet; N R Movva; D Semon; S Escanez; E Kawashima
Journal:  Nucleic Acids Res       Date:  1985-03-25       Impact factor: 16.971

3.  Characterization of human and mouse granulocyte-macrophage-colony-stimulating factors derived from Escherichia coli.

Authors:  J L Schrimsher; K Rose; M G Simona; P Wingfield
Journal:  Biochem J       Date:  1987-10-01       Impact factor: 3.857

4.  Cloning of cDNA for human T-cell replacing factor (interleukin-5) and comparison with the murine homologue.

Authors:  C Azuma; T Tanabe; M Konishi; T Kinashi; T Noma; F Matsuda; Y Yaoita; K Takatsu; L Hammarström; C I Smith
Journal:  Nucleic Acids Res       Date:  1986-11-25       Impact factor: 16.971

5.  Cloning of complementary DNA encoding T-cell replacing factor and identity with B-cell growth factor II.

Authors:  T Kinashi; N Harada; E Severinson; T Tanabe; P Sideras; M Konishi; C Azuma; A Tominaga; S Bergstedt-Lindqvist; M Takahashi
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

6.  Purification and physicochemical characterization of murine T cell replacing factor (TRF).

Authors:  K Takatsu; N Harada; Y Hara; Y Takahama; G Yamada; K Dobashi; T Hamaoka
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

7.  Three-dimensional structure of interleukin-2.

Authors:  B J Brandhuber; T Boone; W C Kenney; D B McKay
Journal:  Science       Date:  1987-12-18       Impact factor: 47.728

8.  Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5).

Authors:  H D Campbell; W Q Tucker; Y Hort; M E Martinson; G Mayo; E J Clutterbuck; C J Sanderson; I G Young
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

9.  Purification and partial sequence analysis of murine B cell growth factor II (interleukin 5).

Authors:  D T McKenzie; H I Filutowicz; S L Swain; R W Dutton
Journal:  J Immunol       Date:  1987-10-15       Impact factor: 5.422

10.  Structure-activity studies of interleukin-2.

Authors:  F E Cohen; P A Kosen; I D Kuntz; L B Epstein; T L Ciardelli; K A Smith
Journal:  Science       Date:  1986-10-17       Impact factor: 47.728
View more
  9 in total

1.  Sequence-specific NMR resonance assignments for human interleukin-5.

Authors:  Hanqiao Feng; Debra L Banville; R D Guiles
Journal:  J Biomol NMR       Date:  2002-08       Impact factor: 2.835

2.  The carboxy-terminal region of human interleukin-5 is essential for maintenance of tertiary structure but not for dimerization.

Authors:  A E Proudfoot; S C Brown; P Graber; F Talabot; C Y Arod; M C Peitsch; M Banks; M McKinnon; R Solari; T N Wells
Journal:  J Protein Chem       Date:  1996-07

3.  In vivo and in vitro folding of a recombinant metalloenzyme, phosphomannose isomerase.

Authors:  A E Proudfoot; L Goffin; M A Payton; T N Wells; A R Bernard
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

4.  A truncated recombinant intercellular adhesion molecule-1 inhibits adhesion of leukemic cell lines to upregulated endothelial cells.

Authors:  L Ross; C M Davis; L Molony
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-12       Impact factor: 2.416

5.  Recombinant human IL-6 expressed in E. coli undergoes selective N-terminal degradation: evidence that the protein consists of a stable core and a nonessential flexible N-terminal.

Authors:  A E Proudfoot; S C Brown; A R Bernard; J Y Bonnefoy; E H Kawashima
Journal:  J Protein Chem       Date:  1993-08

6.  Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist.

Authors:  J Tavernier; T Tuypens; A Verhee; G Plaetinck; R Devos; J Van der Heyden; Y Guisez; C Oefner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

7.  Human interleukin-5 expressed in Escherichia coli has N-terminal modifications.

Authors:  K Rose; P O Regamey; R Anderegg; T N Wells; A E Proudfoot
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

8.  An interleukin 5 mutant distinguishes between two functional responses in human eosinophils.

Authors:  M McKinnon; K Page; I J Uings; M Banks; D Fattah; A E Proudfoot; P Graber; C Arod; R Fish; T N Wells; R Solari
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

9.  3D domain swapping causes extensive multimerisation of human interleukin-10 when expressed in planta.

Authors:  Lotte B Westerhof; Ruud H P Wilbers; Jan Roosien; Jan van de Velde; Aska Goverse; Jaap Bakker; Arjen Schots
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.